SurgeCare

🎉 We are incredibly proud to announce that our co-founders have made the cover of #NatureBiotechnology this month with their groundbreaking article, “Discovery of sparse, reliable omic biomarkers with Stabl,” published in January 2024! This is a significant achievement for Julien Hedou, Grégoire Bellan, Dyani Gaudilliere, Franck Verdonk, Xavier Durand, Brice Gaudilliere, and all the co-authors. Their dedication to advancing bioinformatics with Stabl is helping shape the future of predictive analytics in multi-omic research. #Stabl leverages cutting-edge algorithms to identify the most predictive features within complex multi-omic datasets. This breakthrough promises to significantly impact bioinformatics by facilitating the translation of scientific discoveries into real-world clinical applications, streamlining decision-making processes, and enhancing predictive analytics across various industries. 💡 We are also thrilled to highlight our Creative Director, Clara Leibenguth, whose stunning design was selected for the cover! This milestone reflects the hard work and passion of our team at Surge, and we couldn’t be prouder of this accomplishment! 📖 You can read the full article in open access here: https://lnkd.in/egSuxkB2. 👉 If you’d like to test Stabl on your data, feel free to contact us at info@surge.care. For more information about our technologies, visit biomics.app.

⏳ Only a few days left! Don’t miss the Predictive Biomarkers Seminar, happening this January 22, 2025, from 11:00 AM to 2:00 PM, at Paris Biotech Santé (Cochin campus). With the support of Olink Proteomics, this event will explore how protein and multi-omics biomarkers are revolutionizing the identification of predictive biological signatures with real clinical utility. Agenda Highlights: • Introduction by Julien Hedou, CEO Surge • Talks from experts, including Per Eriksson(Olink), Dr. Franck Verdonk (Surge), and Prof. Italiano Antoine (Gustave Roussy) • Networking lunch to connect with leaders in biomarker innovation Register now (free): https://lnkd.in/eVq4JWNH We look forward to welcoming you for an engaging session on the future of predictive biomarkers. #PredictiveBiomarkers #Surge #PrecisionMedicine #Stabl

🔬 Predictive Biomarkers Seminar – January 22, 2025 We are pleased to invite you to our Predictive Biomarkers seminar, taking place on January 22, 2025, from 11:00 AM to 2:00 PM, at Paris Biotech Santé (Cochin campus). With the support of Olink Proteomics, this event will highlight how protein and multi-omics biomarkers can be leveraged to identify predictive biological signatures with real clinical utility. We will share concrete examples showcasing their integration into translational approaches. Agenda: • Introduction – Julien Hedou, CEO Surge • Leveraging large-scale proteomics – Per Eriksson, Manager Data Science, Olink • From multi-omics analysis to clinical biomarkers: predicting cognitive performance after surgery – Dr. Franck Verdonk, MD, PhD, CMO Surge • Multi-omics integration for predictive biomarkers in immunotherapy – Prof. Italiano Antoine, MD, PhD, Gustave Roussy et Institut Bergonié • Networking lunch 🎯 Register for free (limited seats): https://lnkd.in/eVq4JWNH ____________________________________________________________ 🔬 Predictive Biomarkers Seminar - 22 janvier 2025 Nous avons le plaisir de vous inviter à notre séminaire “Predictive Biomarkers”, qui se tiendra le 22 janvier 2025, de 11h00 à 14h00, à Paris Biotech Santé (site Cochin). Avec le soutien d’Olink Proteomics, cet événement mettra en lumière comment les biomarqueurs protéiques et multiomiques permettent d’identifier des signatures biologiques prédictives présentant une réelle utilité clinique. Nous partagerons des exemples concrets illustrant leur intégration dans des approches translationnelles. Programme : • Introduction – Julien Hedou, CEO Surge • Leveraging large-scale proteomics – Per Eriksson, Manager Data Science, Olink • From multi-omics analysis to clinical biomarkers: predicting cognitive performance after surgery – Dr. Franck Verdonk, MD, PhD, CMO Surge • Multi-omics integration for predictive biomarkers in immunotherapy – Prof. Italiano Antoine, MD, PhD, Gustave Roussy et Institut Bergonié • Networking lunch 🎯 Inscrivez-vous gratuitement (places limitées) : https://lnkd.in/eVq4JWNH #PredictiveBiomarkers #Surge #PrecisionMedicine #Stabl

🚀 I’m excited to share that SurgeCare has been accepted into the Plug and Play Health MedTech Accelerator! At Surge, we’re pushing the boundaries of medical research. Our goal is to leverage multi-omics data analysis to uncover biological signatures and predict medical outcomes, ultimately transforming diagnosis and patient care—especially in surgery. Being part of the Plug and Play MedTech Accelerator is a big milestone for us. Over the next few months, we’ll be honing our go-to-market strategy and working hard to get our innovations out to healthcare providers faster. I’d love to connect with fellow innovators, industry leaders, and potential partners in the Plug and Play network to make a real impact in healthcare together! If you’re interested in learning more or exploring partnership opportunities, feel free to reach out. Thank you to the Plug and Play Health team for their trust and to Zimmer Biomet for this incredible opportunity! We're eager to make a real impact in healthcare and deliver meaningful advances in patient care. #MedTech #HealthcareInnovation #MedicalResearch #MultiOmics #PlugAndPlay #Accelerator

We are thrilled to share that SurgeCare has been honored with a prestigious award from the Fondation Force pour l'Innovation et la Recherche en Santé! At the 2024 Trophées ceremony, our project, Surgelab, was spotlighted as one of six groundbreaking innovations in #diagnostic, #prognostic, and #theranostic fields. This accolade is a key recognition of our commitment to advancing healthcare and improving patient outcomes through cutting-edge solutions. 🌟 We extend our heartfelt gratitude to the Fondation Force, under the leadership of Professor Jean SIBILIA, Lilla Merabet, and Nobel Laureate Professor Jules Hoffmann for recognizing our efforts to decrypt the immune system and supporting us with a generous grant. This funding will be pivotal in driving our research and development forward. A huge congratulations to all the other laureates for their exceptional contributions: 📣 BrightSens Diagnostics: John Volke, Andrey Klymchenko, Elisabete Silva 📣 SUPERBRANCHE: Delphine Felder-Flesch, Richard BOUAOUN 📣 IPHC - Institut Pluridisciplinaire Hubert Curien - CNRS: Dimitri Heintz 📣 Inserm Institute for Translational Medicine and Liver Disease, University of Strasbourg: Emilie Crouchet, Catherine Schuster 📣 Icube: Jonathan Vappou, Gangi Afshin 📣 Solence : Clara Stephenson, Mael Mertad We are excited about the journey ahead and the positive impact Surgelab will bring to the healthcare sector. Stay tuned for more updates on our progress! #Innovation #Healthcare #Surgelab 

Surge advances further in its pursuit of decrypting the immune system to drive precision medicine, with our successful fundraising of €7.5 million ✨ This fundraising round, led by Eurazeo and bolstered by the support of new and old strategic partners including : Boutique Venture Partners, HCVC, 50 Partners Santé, Kima Ventures, MH Innov' and Yann Fleureau, propels us closer to our ambitious objectives. We are positioned to launch of our first product, #PreCyte®, for predicting the risk of postoperative complications, and our premier laboratory, #SurgeLab™, for acquiring individualized immune signatures. Join us on this journey to unlock the secrets of the immune system and redefine precision medicine!🔥 #Surge #PrecisionMedicine #Stabl #Healthcare